AstraZeneca's global CEO Soriot said that China's supply chain is an important and stable pillar of AstraZeneca's global business. Relying on its high quality, high cost-effectiveness and efficient production capacity, we deliver Chinese-made medicines to more than 70 countries and regions around the world. On the same day, the China Development Forum 2025 Annual Meeting was held in Beijing. Soriot said during the forum that the importance of China's continued opening up is self-evident. The core lies in cooperation. Cooperation is the key to the successful development of new drugs. China's open environment will give rise to more cooperation opportunities.